Hyper-entanglement between pulse modes and frequency bins

Hyper-entanglement between two or more photonic degrees of freedom (DOF) can enhance and enable new quantum protocols by allowing each DOF to perform the task it is optimally suited for. Here we demonstrate the generation of photon pairs hyper-entangled between pulse modes and frequency bins. The pulse modes are generated via parametric downconversion in a domain-engineered crystal and subsequently entangled to two frequency bins via a spectral mapping technique. The resulting hyper-entangled state is characterized and verified via measurement of its joint spectral intensity and non-classical two-photon interference patterns from which we infer its spectral phase. The protocol combines the robustness to loss, intrinsic high dimensionality and compatibility with standard fiber-optic networks of the energy-time DOF with the ability of hyper-entanglement to increase the capacity and efficiency of the quantum channel, already exploited in recent experimental applications in both quantum information and quantum computation

5-ethyl-2'-deoxyuridine fragilizes Klebsiella pneumoniae outer wall and facilitates intracellular killing by phagocytic cells

Klebsiella pneumoniae is the causative agent of a variety of severe infections. Many K. pneumoniae strains are resistant to multiple antibiotics, and this situation creates a need for new antibacterial molecules. K. pneumoniae pathogenicity relies largely on its ability to escape phagocytosis and intracellular killing by phagocytic cells. Interfering with these escape mechanisms may allow to decrease bacterial virulence and to combat infections. In this study, we used Dictyostelium discoideum as a model phagocyte to screen a collection of 1,099 chemical compounds. Phg1A KO D. discoideum cells cannot feed upon K. pneumoniae bacteria, unless bacteria bear mutations decreasing their virulence. We identified 3 non-antibiotic compounds that restored growth of phg1A KO cells on K. pneumoniae, and we characterized the mode of action of one of them, 5-ethyl-2'-deoxyuridine (K2). K2-treated bacteria were more rapidly killed in D. discoideum phagosomes than non-treated bacteria. They were more sensitive to polymyxin and their outer membrane was more accessible to a hydrophobic fluorescent probe. These results suggest that K2 acts by rendering the membrane of K. pneumoniae accessible to antibacterial effectors. K2 was effective on three different K. pneumoniae strains, and acted at concentrations as low as 3 μM. K2 has previously been used to treat viral infections but its precise molecular mechanism of action in K. pneumoniae remains to be determined

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients

Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were resistant/refractory to cytotoxic therapy. The overall response rate was 10 of 11 (90.9%; 95% confidence interval [CI] = 58.7% to 99.8%). Disease status at the latest follow-up is as follows: four patients are in complete response (CR) (months >21, >30, >35, >40) under continuous crizotinib administration; 4 patients had progression of disease (months 1, 2, 2, 2); 1 patient obtained CR on crizotinib, received an allogeneic bone marrow transplant, and is in CR; 2 patients (treated before and/or after allogeneic bone marrow transplant) obtained and are still in CR but they have stopped crizotinib. Overall and progression-free survival rates at 2 years are 72.7% (95% CI = 39.1% to 94.0%) and 63.7% (95% CI = 30.8% to 89.1%), respectively. ALK mutations conferring resistance to crizotinib in vitro could be identified in relapsed patients. Crizotinib exerted a potent antitumor activity with durable responses in advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profil

Caracterização das complicações em pacientes submetidos à abdominoplastia: uma revisão bibliográfica / Characterization of complications in patients undergoing abdominoplasty: a review of literature

Este artigo buscou analisar a ocorrência de complicações pós-operatórias em pacientes submetidos à abdominoplastia, evidenciando os tipos mais frequentes, a incidência e as possíveis etiologias. A abdominoplastia possui como objetivo remover a pele em excesso e apertar os músculos abdominais soltos mediante a dissecção limitada do retalho abdominal, plicatura da fáscia do reto abdominal e ressecção tridimensional de um segmento de pele e tecido subdérmico até a fáscia de Scarpa. Mesmo sendo um dos procedimentos cirúrgicos mais realizados no mundo, os riscos de complicações não devem ser ignorados. Esses, comumente, se relacionam às comorbidades do paciente e à escolha técnica cirúrgica associada à experiência do cirurgião. Dentre as possíveis complicações, destacam-se seroma, infecção da ferida operatória, hematoma, deiscência de sutura, necrose de pele, hipertrofia cicatricial, trombose venosa profunda, embolia pulmonar e insatisfação com o resultado. No entanto, ainda são necessários estudos que explorem os impactos que a abdominoplastia, como cirurgia eletiva, pode desencadear na saúde e qualidade de vida do paciente

Luteinizing hormone and follicle-stimulating hormone levels in extreme prematurity: Development of reference intervals

OBJECTIVES. Establishing pediatric reference intervals has always been challenging, with most ranges used in pediatric laboratories developed over many years. The clinical interpretation of gonadotropins is important in the context of ambiguous genitalia. The aim of this study was to develop reference intervals for luteinizing hormone and follicle-stimulating hormone in infants born between 24 and 29 weeks' gestation. METHODS. Samples were collected at 0 to 43 days after birth from 82 premature infants born <30 weeks' gestation for analysis of luteinizing hormone and follicle-stimulating hormone by automated immunochemiluminometric immunoassays. RESULTS.The 43 male infants demonstrated a range of luteinizing hormone levels from 0.1 to 13.4 IU/L and of follicle-stimulating hormone levels from 0.3 to 4.6 IU/L. The 39 female infants demonstrated a range of luteinizing hormone levels from 0.2 to 54.4 IU/L and of follicle-stimulating hormone levels from 1.2 to 167.0 IU/L. The ratio of luteinizing hormone/follicle-stimulating hormone levels differed with males, ranging from 0.3 to 9.4, and females, at <0.5. CONCLUSION.These data provide guidance for the interpretation of luteinizing hormone and follicle-stimulating hormone levels for the first 6 weeks of life in extremely premature infants born between 24 and 29 weeks' gestation. The availability of age-appropriate reference intervals is essential for correct and timely interpretation of biochemical results to the clinician. Copyright © 2008 by the American Academy of Pediatrics